Table 3.
Characteristics | Colorectal cancer (n=83), n (%)a | Breast cancer (n=28), n (%) | Cervical cancer (n=19), n (%) | Total (N=101), n (%) | |||||
Using single or multiple HIT tools | |||||||||
|
Single HIT tools | 53 (63.9) | 22 (78.6) | 14 (73.7) | 66 (65.3) | ||||
|
Multiple HIT tools | 30 (36.1) | 6 (21.4) | 5 (26.3) | 35 (34.7) | ||||
HIT sources | |||||||||
|
EHRb based | 74 (89.2) | 20 (71.4) | 18 (94.7) | 85 (84.2) | ||||
|
Web based | 11 (13.3) | 9 (32.1) | 3 (15.8) | 18 (17.8) | ||||
|
Other or unclear | 15 (18.1) | 3 (10.7) | 3 (15.8) | 19 (18.8) | ||||
HIT functions | |||||||||
|
CDSc panel management or outreach | 50 (60.2) | 7 (25) | 9 (47.4) | 57 (56.4) | ||||
|
CDS point of care | 41 (49.4) | 16 (57.1) | 12 (63.2) | 48 (47.5) | ||||
|
Risk identification | 13 (15.7) | 5 (17.9) | 6 (31.6) | 18 (17.8) | ||||
|
Patient decision aid | 13 (15.7) | 9 (32.1) | 2 (10.5) | 18 (17.8) | ||||
|
Provider assessment and feedback | 11 (13.3) | 1 (3.6) | 1 (5.3) | 12 (11.9) | ||||
|
Tracking patient adherence | 27 (32.5) | 4 (14.3) | 6 (31.6) | 30 (29.7) | ||||
|
Other | 3 (3.6) | —d | — | 3 (3.0) | ||||
Cancer screening activities supported by HIT | |||||||||
|
Panel management | 50 (60.2) | 8 (28.9) | 7 (36.8) | 56 (55.4) | ||||
|
Point of care | 39 (47) | 15 (53.6) | 12 (63.2) | 45 (44.6) | ||||
|
Follow-up (referral) | 36 (43.4) | 7 (25.0) | 7 (36.8) | 41 (40.6) | ||||
|
Follow-up (abnormal or positive result) | 12 (14.5) | 2 (7.1) | 5 (26.3) | 17 (16.8) | ||||
|
Acquire previous results | 7 (8.4) | 2 (7.1) | 4 (21.1) | 10 (9.9) | ||||
|
Other | 21 (25.3) | 11 (39.3) | 5 (26.3) | 24 (23.8) |
aPercentages were calculated based on column totals. Some studies featured >1 HIT source, function, and cancer screening activity. As a result, these categories are not mutually exclusive and will not necessarily sum to 100%. Refer to Multimedia Appendix 4 for definitions of the terms used in this table.
bEHR: electronic health record.
cCDS: clinical decision support.
dNot available.